Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential
TipRanksMar 4 06:30 ET
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
TipRanksMar 4 06:31 ET
Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks
TipRanksMar 1 01:08 ET
HW Wainwright Cuts Aclaris to Neutral, Cites Underwhelming Study Data
Seeking AlphaJan 22 17:55 ET
Aclaris Therapeutics Analyst Ratings
BenzingaJan 22 07:13 ET
Aclaris Therapeutics (ACRS) Was Downgraded to a Hold Rating at BTIG
TipRanksJan 16 05:25 ET
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aclaris Therapeutics (ACRS) and Quanterix (QTRX)
TipRanksJan 15 00:20 ET
Aclaris Therapeutics Analyst Ratings
BenzingaJan 11 08:10 ET
Aclaris Downgraded at Jefferies Despite Mid-stage Win for Eczema Therapy
Seeking AlphaJan 10 15:09 ET
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)
TipRanksJan 2 07:02 ET
Aclaris Therapeutics Analyst Ratings
BenzingaDec 29, 2023 09:24 ET
Buy Rating Justified by Aclaris Therapeutics' Strategic Focus and Robust Financial Management
TipRanksDec 29, 2023 08:45 ET
Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
TipRanksDec 20, 2023 21:05 ET
Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1
BenzingaDec 18, 2023 09:22 ET
Aclaris Therapeutics Analyst Ratings
BenzingaDec 18, 2023 09:21 ET
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $9
BenzingaNov 14, 2023 09:32 ET
The Latest Analyst Ratings for Aclaris Therapeutics
BenzingaNov 14, 2023 08:00 ET
Hold Rating on Aclaris Therapeutics: Unfavorable ATI-450 Trial Results and Uncertainty on Upcoming ATI-1777 Trial
TipRanksNov 14, 2023 04:16 ET
Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS), Aclaris Therapeutics (ACRS) and CryoPort (CYRX)
TipRanksNov 13, 2023 19:40 ET
Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating
MT NewswiresNov 13, 2023 15:00 ET
No Data
No Data